Validation of CALLY index predicts biochemical recurrence in prostate cancer, suggesting improved risk assessment.
The pre-treatment CALLY index represents a readily available biomarker that independently predicts BCR and may complement established risk stratification tools in prostate cancer, although model performance was modest. External validation in prospective cohorts with longer followup is necessary before clinical implementation.
No takes yet. Share an insight, caveat, or question.
Özdeş et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: